Connect with us

Biotech

Abi Health Raises €2 Million to Grow in the U.S.

Currently, Abi Health has 25 employees and plans to expand the workforce to 60 employees once the financing round is closed, a fact expected this fall. The company’s intention is for two-thirds of the workforce to be located at its Barcelona headquarters. Until 2024, the goal of Abi Health is to grow at a rate of 150% per year, as explained by the company’s medical director.

Published

on

Abi Health raises capital. The Spanish-Irish company specializing in telehealth has raised €2 million that it will use to expand in the U.S. and Asian markets, according to Víctor Vicens, the company’s medical director.

The biotech company has received support from an Austrian and a Spanish fund, whose names have not been disclosed. The Barcelona-based company plans to close another €3 million tranche in the coming months. The aim of this operation is to ensure operations in 35 countries, to work with 1,000 physicians, and to have a presence in all the countries of the European Union (EU).

Abi Health is considered a “hybrid system between Uber and Teladoc, although oriented towards telehealth,” explained Vicens. The company has an interactive robot that mediates between the user and a doctor. For each consultation resolved, the healthcare professional monetizes economic compensation.

Find more details about Abi Health and read the most important financial news of the day with our companion app Born2Invest.

Abi Health has an interactive robot that mediates between the user and a doctor

The company already has a presence in the U.S. market. However, in this country, for the moment, Abi Health has only been implemented as a consultation tool with nurses, and not with doctors, due to cost and regulatory issues. In the Americas, the company is working with Reckitt to offer pediatric services. On a global scale, Zurich and Allianz are also strategic allies of the company.

Beyond the financing round, Abi Health is also working on various projects with “different pharmaceutical giants,” Vicens said. For now, the company is already working on a product aimed at treating diabetes.

SEE ALSO  How to hack your consumers’ memory for better marketing

The company had a turnover of more than €1 million in 2021, more than doubling sales from the previous year. Until 2024, the goal of Abi Health is to grow at a rate of 150% per year, as explained by the company’s medical director.

Abi Health billed more than one million euros in 2021

Currently, Abi Health has 25 employees and plans to expand the workforce to 60 employees once the financing round is closed, a fact expected this fall. The company’s intention is for two-thirds of the workforce to be located at its Barcelona headquarters.

The company was founded in 2016 and within two years began working in five countries: Spain, France, Italy, Germany, and the United Kingdom. In 2019, it raised two million euros financed mainly by a Lithuanian family office, plus another two smaller ones.

__

(Featured image by tmeier1964 via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Anthony Donaghue writes about science and technology. Keeping abreast of the latest tech developments in various sectors, he has a keen interest on startups, especially inside and outside of Silicon Valley. From time to time, he also covers agritech and biotech, as well as consumer electronics, IT, AI, and fintech, among others. He has also written about IPOs, cannabis, and investing.